Abstract:Alzheimer's disease (AD) is characterized by β-amyloid (Aβ) aggregation and neuroinflammation, leading to a progressive synaptic loss and cognitive decline. Recent evidence highlights Galectin-3 (Gal-3) as a crucial factor in Aβ pathogenesis, yet effective strategies to simultaneously target Gal-3 and Aβ are currently insufficient. This study assesses the therapeutic efficacy of D30, an innovative anti-AD compound manifested promising effects on reducing Aβ deposition and alleviating neuronal damage in scopolamine-induced AD models. In our study, we administered neurotoxic oligomeric Aβ (oAβ) to mice and observed increased Gal-3 deposition and microglial activation in the hippocampus, leading to significant cognitive impairments. Similarly, in the 5 × FAD mouse model, known for Aβ overproduction, there was a progressive rise in Gal-3 levels and glial cell activation. We then investigated the effects of D30 on 5 × FAD mice, focusing on its modulation of Gal-3 and Aβ and impact on neuroinflammatory responses. D30 effectively reduced Aβ monomer production by inhibiting the expression of Amyloid Precursor Protein (APP) and presenilin 1 (PS1), as well as decreasing Aβ oligomer aggregation. Treatment with D30 not only improved cognitive functions but also reversed dendritic spine loss and increased PSD95 expression in 5 × FAD mice. Notably, D30 significantly lowered Gal-3 levels in both plasma and hippocampal tissues. Mechanistic studies revealed that D30 binds to Gal-3 and disrupts the interaction between Gal-3 and the triggering receptor expressed on myeloid cells 2 (TREM2), as confirmed by fluorescence resonance energy transfer (FRET) and microscale thermophoresis (MST). Our findings underscore the interaction between Gal-3 and Aβ in AD and its role in systemic inflammation using the 5 × FAD mouse model. Being able to target and regulate Gal-3 together with Aβ is crucial for preventing neuroinflammation and protecting neurons, D30 emerged as a novel compound with promising potential for AD treatment. Aims: Alzheimer's disease (AD) is characterized by β-amyloid (Aβ) aggregation and neuroinflammation, leading to progressive synaptic loss and cognitive decline. Recent evidence suggests that Galectin-3 (Gal-3) plays a critical role in Aβ pathogenesis. However, strategies to simultaneously target Gal-3 and Aβ are currently insufficient. This study evaluates the therapeutic efficacy of D30, in reducing Gal-3 and Aβ pathogenesis. Materials and methods: We applied exogenous oligomeric Aβ and used 5 × FAD mice to assess the impact of Aβ on Gal-3 deposition, microglial activation, and cognitive function. Thy1-EGFP mice were employed to observe dendritic spines. Comprehensive evaluations of D30's effects included behavioral studies, transcriptomic analysis, Western blotting, and immunofluorescent staining. The interaction between D30 and Gal-3 was examined using fluorescence resonance energy transfer (FRET) and microscale thermophoresis (MST). Key findings: D30 effectively reduced Aβ monomer production by inhibiting Amyloid Precursor Protein (APP) and presenilin 1 (PS1) expression, and decreased Aβ aggregation. Treatment with D30 improved cognitive functions, reversed dendritic spine loss, and increased PSD95 expression in 5 × FAD mice. Additionally, D30 significantly lowered Gal-3 levels in both plasma and hippocampal tissues. D30 binds to Gal-3 and disrupts the interaction between Gal-3 and TREM2, as confirmed by FRET and MST. Significance: Our findings underscore the interaction between Gal-3 and Aβ in AD and its role in systemic inflammation using the 5 × FAD mouse model. Being able to target and regulate Gal-3 together with Aβ is crucial for preventing neuroinflammation and protecting synapses, D30 emerged as a novel compound with promising potential for AD treatment.

Diethyl butylmalonate attenuates cognitive deficits and depression in 5×FAD mice

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease

DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway

Dorsal raphe nucleus-hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5×FAD male mice

Early intervention using long-term rhythmic pulsed magnetic stimulation alleviates cognitive decline in a 5xFAD mouse model of Alzheimer's disease

Exenatide Alleviates Mitochondrial Dysfunction and Cognitive Impairment in the 5×FAD Mouse Model of Alzheimer’s Disease

2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione Ameliorates Diabetic Cognitive Impairment Through Inhibiting Hif3α and Apoptosis

Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease

Exploring Dimethylsulfoniopropionate as a potential treatment for Alzheimer's disease: A study using the 3 × Tg-AD mouse model

Altered synaptic currents, mitophagy, mitochondrial dynamics in Alzheimer's disease models and therapeutic potential of Dengzhan Shengmai Capsules intervention

Dendrobium nobile Lindl alkaloid and metformin ameliorate cognitive dysfunction in senescence-accelerated mice via suppression of endoplasmic reticulum stress

Danggui Buxue decoction ameliorates mitochondrial biogenesis and cognitive deficits through upregulating histone H4 lysine 12 acetylation in APP/PS1 mice

Imbalance of multiple neurotransmitter pathways leading to depression-like behavior and cognitive dysfunction in the triple transgenic mouse model of Alzheimer disease

Electroacupuncture attenuates cognition impairment via anti-neuroinflammation in an Alzheimer’s disease animal model

Dendrobine Ameliorates Alzheimer's Disease-like Pathology and Cognitive Decline in 3 × Tg-AD Mice

Compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one downregulation of Galectin-3 ameliorates Aβ pathogenesis-induced neuroinflammation in 5 × FAD mice

Ellagic Acid(ea) Ameliorates Alzheimer’s Disease by Reducing Aβ Levels, Oxidative Stress and Attenuating Inflammation

Dihydromyricetin Ameliorates Behavioral Deficits and Reverses Neuropathology of Transgenic Mouse Models of Alzheimer’s Disease

Dopamine D1 receptor agonist A-68930 ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice

Bazhu Decoction, a Traditional Chinese Medical Formula, Ameliorates Cognitive Deficits in the 5xfad Mouse Model of Alzheimer’s Disease